CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

E. G. Chiorean, D. D. Von Hoff, M. Reni, F. P. Arena, J. R. Infante, V. G. Bathini, T. E. Wood, P. N. Mainwaring, R. T. Muldoon, P. R. Clingan, V. Kunzmann, R. K. Ramanathan, J. Tabernero, D. Goldstein, D. McGovern, B. Lu, A. Ko

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Fingerprint

Dive into the research topics of 'CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Nursing and Health Professions

Keyphrases